Yahoo Finance11d
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...
Business Wire10d
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Act…
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has be ...
Business Insider10d
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...
ETF Daily News14d
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Buy” by Brokerages
Humacyte has a 52 week low of $2.45 and a 52 week high of $9.97. The stock has a 50-day moving average price of $5.24 and a 200 day moving average price of $6.17.
Business Insider5d
Humacyte, Inc. Is Being Sued For Violating Securities Regulations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of ...
The Business Journals24d
Shareholder lawsuit shines light on biotech's FDA woes
Shareholders accuse Humacyte of misleading investors about quality issues. STORY HIGHLIGHTS Shareholders accuse Humacyte of misleading investors about quality issues. Humacyte's stock fell after ...
Yahoo Finance22d
Insider Buyers At Humacyte Likely Disappointed With 17% Slide
Insiders who acquired US$775.1k worth of Humacyte, Inc.'s (NASDAQ:HUMA) stock at an average price of US$6.64 in the past 12 months may be dismayed by the recent 17% price decline. Insiders ...
Yahoo Finance10d
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...
CNN24d
Sticker shock on car prices, books are back, world’s best cheese: Catch up on the day’s stories
1️⃣ Sticker shock: If you haven’t been car shopping in a while, brace yourself. Americans paid a whopping $47,612 on average for a new car last month — nearly $10,000 more than they did ...
Morningstar7d
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman
Humacyte, Inc. (HUMA) Securities Class Action: The lawsuit claims that Humacyte and certain of its executives failed to disclose material adverse facts about the company’s business, operations ...
Stockhouse6d
Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman
San Francisco, California--(Newsfile Corp. - December 6, 2024) - Humacyte, a biotechnology company focused on regenerative medicine, is now facing an investor class action alleging that the company ...
Stockhouse5d
Humacyte, Inc. Is Being Sued For Violating Securities Regulations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...